Harnessing Cellular Immunotherapy for EBV-Associated Malignancies: Current Advances and Future Directions

Area of Science:

• Oncology and Immunology
• Cellular Therapy
• Viral Malignancies

Background:

• Standard treatments for EBV-associated malignancies lack efficacy in relapsed/refractory cases.
• There is a critical need for novel therapeutic strategies.
• Immunotherapy, especially T cell-based approaches, is emerging as a promising alternative.

Purpose of the Study:

• To review the rationale behind Epstein-Barr virus (EBV)-directed cellular therapies.
• To outline current clinical applications of these therapies.
• To discuss limitations and future opportunities for optimizing EBV-targeted cellular treatments.

Main Methods:

• Review of preclinical and clinical data on EBV-specific cytotoxic T lymphocytes and dendritic cell vaccines.
• Analysis of engineered T cell therapies, including T-cell receptor (TCR) and chimeric antigen receptor (CAR) approaches targeting EBV antigens (LMP1, gp350).
• Comparison of cellular immunotherapy with conventional chemotherapy and radiotherapy.

Main Results:

• EBV-specific T cell therapies demonstrate potential for both treatment and prevention of EBV-associated malignancies.
• Engineered T cell therapies (TCR, CAR) targeting EBV antigens are advancing in clinical development.
• Cellular immunotherapy exhibits a favorable safety profile, robust in vivo T cell expansion, and potent antitumor effects compared to conventional therapies.

Conclusions:

• EBV-directed cellular therapies represent a promising advancement over traditional treatments for EBV-associated cancers.
• Further refinement of therapeutic protocols is essential to maximize efficacy and accessibility.
• Ongoing research aims to overcome current limitations and optimize these innovative immunotherapeutic strategies.